Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 a… Read more
Market Cap & Net Worth: Jiangsu Kanion Pharmaceutical Co Ltd (600557)
Jiangsu Kanion Pharmaceutical Co Ltd (SHG:600557) has a market capitalization of $1.10 Billion (CN¥8.05 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #9036 globally and #1813 in its home market, demonstrating a 2.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Kanion Pharmaceutical Co Ltd's stock price CN¥14.22 by its total outstanding shares 566158806 (566.16 Million).
Jiangsu Kanion Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Jiangsu Kanion Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.57 Billion to $1.10 Billion (-2.66% CAGR).
Jiangsu Kanion Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Kanion Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.27x
Jiangsu Kanion Pharmaceutical Co Ltd's market cap is 0.27 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.68x
Jiangsu Kanion Pharmaceutical Co Ltd's market cap is 2.68 times its annual earnings
9.89x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.57 Billion | $2.82 Billion | $362.34 Million | 0.56x | 4.33x |
| 2016 | $1.28 Billion | $3.00 Billion | $373.74 Million | 0.43x | 3.43x |
| 2017 | $1.02 Billion | $3.27 Billion | $373.78 Million | 0.31x | 2.74x |
| 2018 | $784.19 Million | $3.82 Billion | $414.05 Million | 0.21x | 1.89x |
| 2019 | $1.13 Billion | $4.57 Billion | $506.99 Million | 0.25x | 2.23x |
| 2020 | $784.74 Million | $3.03 Billion | $262.92 Million | 0.26x | 2.98x |
| 2021 | $944.47 Million | $3.65 Billion | $320.54 Million | 0.26x | 2.95x |
| 2022 | $1.45 Billion | $4.35 Billion | $434.47 Million | 0.33x | 3.33x |
| 2023 | $1.58 Billion | $4.86 Billion | $464.16 Million | 0.33x | 3.41x |
| 2024 | $1.05 Billion | $3.90 Billion | $391.86 Million | 0.27x | 2.68x |
Competitor Companies of 600557 by Market Capitalization
Companies near Jiangsu Kanion Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Jiangsu Kanion Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Jiangsu Kanion Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jiangsu Kanion Pharmaceutical Co Ltd's market cap moved from $1.57 Billion to $ 1.10 Billion, with a yearly change of -2.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.10 Billion | +0.78% |
| 2025 | CN¥1.09 Billion | +3.60% |
| 2024 | CN¥1.05 Billion | -33.63% |
| 2023 | CN¥1.58 Billion | +9.44% |
| 2022 | CN¥1.45 Billion | +53.19% |
| 2021 | CN¥944.47 Million | +20.35% |
| 2020 | CN¥784.74 Million | -30.62% |
| 2019 | CN¥1.13 Billion | +44.23% |
| 2018 | CN¥784.19 Million | -23.37% |
| 2017 | CN¥1.02 Billion | -20.08% |
| 2016 | CN¥1.28 Billion | -18.41% |
| 2015 | CN¥1.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Jiangsu Kanion Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.10 Billion USD |
| MoneyControl | $1.10 Billion USD |
| MarketWatch | $1.10 Billion USD |
| marketcap.company | $1.10 Billion USD |
| Reuters | $1.10 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.